Welcome to our dedicated page for Silence Therapeutics Plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silence Therapeutics plc (Nasdaq: SLN) SEC filings page brings together the company’s regulatory disclosures as a global clinical-stage biotechnology issuer. Through documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, Silence provides detailed information on its siRNA-based pipeline, financial condition and governance.
In its filings and furnished press releases, the company discusses the development of divesiran, a first-in-class siRNA candidate for polycythemia vera (PV), including Phase 1 and Phase 2 SANRECO study design, clinical data highlights and regulatory designations such as U.S. FDA Fast Track and Orphan Drug status for PV. Filings also reference other programs from the mRNAi GOLD™ platform, including zerlasiran (SLN360) for cardiovascular disease, SLN312 licensed to AstraZeneca and SLN548 for complement-mediated diseases, as well as early extra-hepatic siRNA targeting efforts.
Silence’s periodic reports provide quantitative data on research and development expenses, general and administrative costs, net losses, cash and short-term investment balances and contract liabilities. Risk factor sections and management commentary outline uncertainties related to clinical development, regulatory approvals, collaborations, manufacturing and intellectual property.
Current reports on Form 8-K document material events such as quarterly and annual financial results, completion of clinical trial enrollment milestones, leadership and Board changes, director resignations, and outcomes of shareholder votes at the annual general meeting. These filings also confirm that the company’s American Depositary Shares, each representing three ordinary shares, are listed on The Nasdaq Stock Market LLC under the symbol SLN.
On Stock Titan, SEC filings for SLN are updated in near real time from EDGAR, and AI-powered summaries help explain the key points in lengthy documents. Users can quickly scan 10-K and 10-Q reports, review 8-K event disclosures and track how Silence Therapeutics’ siRNA programs, financial profile and governance structure evolve over time.
Silence Therapeutics plc is a UK-based biotechnology company developing short interfering RNA (siRNA) medicines using its mRNAi GOLD™ liver-targeted platform. Its lead rare disease program, divesiran (SLN124), is in a fully enrolled Phase 2 SANRECO trial for polycythemia vera, with topline results expected in the third quarter of 2026.
Cardiometabolic pipeline assets include zerlasiran (SLN360), a Phase 3–ready siRNA targeting Lp(a) for cardiovascular disease, SLN312 targeting ANGPTL3, SLN365 for cholesterol via GPR146, and SLN098 for obesity via INHBE, all designed for potent, infrequent subcutaneous dosing. The company believes existing cash, cash equivalents and anticipated milestone payments from current collaborations can fund operations into 2028.
Silence has collaboration histories with AstraZeneca and Hansoh. AstraZeneca advanced SLN312 into Phase 1 with multiple milestone payments but decided on March 4, 2026 not to pursue development beyond Phase 1, after which Silence will regain full global rights. Hansoh paid upfront and milestone amounts on three siRNA targets but elected in December 2024 not to continue development, leaving Silence with worldwide rights to those programs.
Silence Therapeutics reported a larger full-year 2025 net loss while highlighting progress across its siRNA pipeline. Collaboration revenue dropped to $0.6M from $43.3M, driving a wider net loss of $88.6M, or $0.63 per share, versus a $45.3M loss in 2024.
Cash, cash equivalents and short-term investments totaled $85.1M as of December 31, 2025. The company emphasized divesiran for polycythemia vera, with the Phase 2 SANRECO trial fully enrolled and topline results expected in 3Q 2026, and completed core Phase 3 readiness work for zerlasiran in high Lp(a).
AstraZeneca completed a Phase 1 interim analysis of SLN312 in dyslipidemia and then decided not to pursue development beyond Phase 1, after which Silence will regain exclusive global rights. Silence also advanced new preclinical programs SLN365 and SLN098 and noted leadership changes with Iain Ross serving as Interim Principal Executive Officer.
Silence Therapeutics plc’s 10% owner reported internal ADS transfers with no net change in economic exposure. On August 3, 2025, Ora Capital Limited sold 20,000 American Depositary Shares (ADS) at $5.45 per ADS while Richard Ian Griffiths purchased the same amount. On October 27, 2025, OCL sold a further 2,000 ADS at $7.75 per ADS, again matched by Griffiths buying 2,000 ADS. The filing states these are essentially internal transfers with no change in total beneficial holding, and that each ADS is convertible into three ordinary shares for no consideration.
Lombard Odier Asset Management (USA) Corp reports beneficial ownership of 5,935,955 ordinary shares of Silence Therapeutics plc, representing 4.2% of the company. This holding includes 1,978,650 American Depositary Shares, each representing three ordinary shares.
The ownership percentage is calculated using 141,701,848 ordinary shares issued and outstanding as of October 30, 2025. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.
Silence Therapeutics plc reported a new stock option grant to director David Lemus. On January 2, 2026, he received a share option covering 90,000 ordinary shares with an exercise price of $2.05 per share and no cost for the grant itself. The option is scheduled to vest in equal monthly installments over one year, beginning one month after January 2, 2026, as long as he continues to serve the company on each vesting date. The option expires on January 2, 2036, and gives him the right to buy company shares in the future at the fixed exercise price.
Silence Therapeutics plc is undergoing significant leadership changes, as President, Chief Executive Officer and director Craig Tooman agreed by mutual consent to end his employment and step down from the Board effective December 14, 2025.
On the same date, Board Chairman Iain Ross was appointed as interim principal executive officer, with additional compensation terms still to be determined and to be covered in a later amendment. The Board also appointed James Ede-Golightly, age 46, to serve as a director with an initial term running until the Company’s 2026 annual general meeting, with his director compensation to be finalised later. The Company issued a December 15, 2025 press release about these changes, filed as Exhibit 99.1.
Silence Therapeutics plc reported third‑quarter results reflecting lower collaboration revenue and ongoing R&D investment. Revenue was $159 thousand in Q3 2025 versus $1.498 million a year ago, mainly due to fewer recognized AstraZeneca milestones. Net loss was $20.958 million (vs. $35.544 million), with operating expenses of $20.544 million in R&D and $5.795 million in G&A.
For the first nine months, revenue was $525 thousand (vs. $17.953 million) and net loss was $76.842 million (vs. $57.611 million). Cash, cash equivalents and short‑term investments totaled $102.2 million as of September 30, 2025, and management believes existing liquidity and anticipated collaboration milestones can fund operations into 2028. Contract liabilities tied to the AstraZeneca collaboration were $55.552 million, to be recognized over future periods.
Pipeline updates note divesiran (SLN124) Phase 2 SANRECO enrollment completed in October 2025, with initial topline results anticipated in the third quarter of 2026. Zerlasiran (SLN360) completed Phase 3 readiness activities, with partnering sought for Phase 3 and potential commercialization. Shares outstanding were 141,701,848 as of October 30, 2025.
Silence Therapeutics plc furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent business highlights. The press release is provided as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company’s American Depositary Shares trade on Nasdaq under SLN, with each ADS representing 3 ordinary shares of nominal value £0.05 per share.
Silence Therapeutics plc reported a clinical milestone under Other Events: it has completed enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV).
The company furnished a press release as Exhibit 99.1. The information, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
Silence Therapeutics plc reported that Michael Davidson resigned from its board of directors on August 11, 2025, stepping down immediately from the Board and from the Audit and Risk, Remuneration, and Science & Technology Committees. The company states that he left to focus on other time commitments, including his role as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and that his resignation was not due to any disagreement with the company, its management, or the Board.
After his departure, the Board reduced its size from five to four directors. The Board also appointed its chairman, Iain Ross, to the Audit and Risk Committee to fill the vacancy created by Dr. Davidson’s resignation, maintaining coverage of this key governance function.